Please use this identifier to cite or link to this item:
|Title:||Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.||Austin Authors:||Komatsu, Nobukazu;Jackson, Heather M;Chan, Kok-fei;Oveissi, Sara;Cebon, Jonathan S ;Itoh, Kyogo;Chen, Weisan||Affiliation:||Ludwig Institute for Cancer Research Melbourne-Austin Branch, Heidelberg, VIC 3084, Australia||Issue Date:||27-Feb-2013||Publication information:||Molecular Immunology 2013; 54(3-4): 465-71||Abstract:||The tumor antigen NY-ESO-1 is one of the most antigenic cancer-testis antigens, first identified by serologic analysis of a recombinant cDNA expression library (SEREX). NY-ESO-1 is expressed in different types of cancers including melanoma. NY-ESO-1-specific spontaneous humoral and cellular immune responses are detected in a large proportion of patients with advanced NY-ESO-1-expressing cancers. Therefore NY-ESO-1 is a good candidate antigen for immunotherapy. Although cellular immune responses to NY-ESO-1 are well characterized, much less is known about the humoral immune responses. In this study, we finely mapped linear antibody epitopes using sera from melanoma patients and shorter overlapping peptide sets. We have shown that melanoma patients' humoral immune systems responded to NY-ESO-1 differently in each individual with widely differing antibody specificity, intensity and antibody subtypes. This knowledge will help us further understand anti-tumor immunity and may also help us to monitor cancer progress and cancer vaccine efficacy in the future.||Gov't Doc #:||23454162||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11689||DOI:||10.1016/j.molimm.2013.01.014||URL:||https://pubmed.ncbi.nlm.nih.gov/23454162||Type:||Journal Article||Subjects:||Adult
Aged, 80 and over
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.